药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
Urelumab
The risk or severity of adverse effects can be increased when Urelumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Visilizumab
The risk or severity of adverse effects can be increased when Visilizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Gantenerumab
The risk or severity of adverse effects can be increased when Gantenerumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Benralizumab
The risk or severity of adverse effects can be increased when Benralizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Rilotumumab
The risk or severity of adverse effects can be increased when Rilotumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Crenezumab
The risk or severity of adverse effects can be increased when Crenezumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Avelumab
The risk or severity of adverse effects can be increased when Avelumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Varlilumab
The risk or severity of adverse effects can be increased when Varlilumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Lebrikizumab
The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Vadastuximab Talirine
The risk or severity of adverse effects can be increased when Vadastuximab Talirine is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Romosozumab
The risk or severity of adverse effects can be increased when Romosozumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Landogrozumab
The risk or severity of adverse effects can be increased when Landogrozumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Seribantumab
The risk or severity of adverse effects can be increased when Seribantumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ligelizumab
The risk or severity of adverse effects can be increased when Ligelizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ublituximab
The risk or severity of adverse effects can be increased when Ublituximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Emibetuzumab
The risk or severity of adverse effects can be increased when Emibetuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Dalotuzumab
The risk or severity of adverse effects can be increased when Dalotuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Trastuzumab deruxtecan.